MSC – Page 2 – Communicable Diseases Research

The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

코로나19 환자를 위한 중간엽 기질세포의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2022-08-012022-09-11
Journal: Journal of infection and public health [Category] 신약개발, 임상,

Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

2019년 코로나바이러스로 인한 급성호흡곤란증후군에 대한 중간엽 기질세포 치료

Article

Published on 2022-08-012022-09-12
Journal: Cytotherapy [Category] 진단,

[키워드] 95% CI 95% confidence interval acute lung injury acute respiratory distress acute respiratory distress syndrome Allogeneic anti-inflammatory property ARDS C-reactive protein case sery cells clinical outcomes coronavirus disease COVID-19 COVID-19-associated ARDS declined discharged dose eligible follow-up period high mortality hospital Inflammatory cytokine intensive care Kidney injury less liver Lung disease mechanical ventilation mechanically ventilated median time Mesenchymal stromal cell Mesenchymal stromal cells moderate MSC MSCs nine Patient patients patients died remained Remestemcel-L requiring supplemental oxygen resulting Safe shown significantly stromal cell syndrome therapy treat treated were excluded
[DOI] 10.1016/j.jcyt.2022.03.006 PMC 바로가기 [Article Type] Article

Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19

급성 폐 손상에서 중간엽 줄기 세포의 면역 조절: 전임상 동물 모델에서 중증 COVID-19 치료까지

Review

Published on 2022-07-252022-09-11
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종,

[키워드] acute lung injury acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 animal animal model antiviral properties antiviral property caused Cell Cell therapy clinical trial clinical trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Cytokine storm highlight immunomodulation immunomodulatory Infection lung Lung injury mass Mesenchymal stem cells Model Mortality MSC MSC therapy MSCs outcome pandemic Pathogenesis patients with COVID-19 potential mechanism potential mechanisms Preclinical public health Reinfection respiratory distress Respiratory distress syndrome risk SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus STEM stem cells syndrome the SARS-CoV-2 tissue repair treat vaccination vaccine breakthrough infection vaccine breakthrough infections Viral variants
[DOI] 10.3390/ijms23158196 PMC 바로가기 [Article Type] Review

Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval

COVID-19를 치료하기 위한 중간엽 간질 세포의 통제된 시험에 대한 업데이트된 살아있는 체계적인 검토 및 메타 분석: 신속한 승인-빠른 승인을 위한 시험 증거의 가속화된 합성을 위한 프레임워크

Meta-Analysis

Published on 2022-07-202022-09-11
Journal: Stem cells translational medicine [Category] 임상,

[키워드] accelerate accelerated acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 appear approval ARDS Clinical studies clinical study conducted Consistency Control Controlled controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria Critical death Endpoint evaluate Evidence Exosomes Extracellular Extracellular vesicles facilitate framework heterogeneity Hospital stay identify IMPROVE ISCT Master protocol mean difference Mesenchymal stem cells Mesenchymal stromal cell Mesenchymal stromal cells Meta-analysis Microvesicles moderate Mortality MSC MSC-EVs exosomes MSCs non-randomized study outcome Oxygenation Patient Pneumonia PROSPERO protocol random-effect random-effects Random-effects meta-analysis Randomized controlled trial Rapid reduce reduce mortality Relative risk reported respiratory distress Respiratory distress syndrome review risk of bia risk of death RoB SARS-CoV-2 Sepsis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Society stromal cell stromal cells synthesis systematic review treat Treatment
[DOI] 10.1093/stcltm/szac038 PMC 바로가기 [Article Type] Meta-Analysis

Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19

중증 코로나바이러스 질환 치료를 위한 중간엽 줄기세포의 면역조절 측면 탐색 19

Review

Published on 2022-07-122022-09-11
Journal: Cells [Category] COVID19(2023년), SARS, 치료법,

[키워드] ACE-2 acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 acute respiratory syndrome coronavirus-2 administration affected Alpha alveolar epithelial cell alveolar epithelial cells angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anti-apoptotic Anti-inflammatory anti-oxidative aspect Asymptomatic average Betacoronavirus breathlessness cause cellular characterized chemokines chest pain Clinical outcome Clinical symptoms colony-stimulating factor coronavirus 2 COVID-19 COVID-19 patient Critically ill critically ill COVID-19 patients curative cytokine Cytokine storm Cytokine storms damaged dependent on Deterioration disease severity dry cough Effectiveness Effects elicited endothelial engage enzyme epithelial cells excessive inflammation family Coronaviridae fatigue Fever fibroblast fibroblast growth factor functional GCSF genus genus Betacoronavirus granulocyte granulocyte colony-stimulating factor growth factor Growth factors Health healthy histological IL-6 IL-7 IL-8 IL-9 immune cells immune response immune responses immunomodulation immunomodulatory immunomodulatory capabilities immunomodulatory capability Incubation period individual infected individual infected individuals infiltrating immune cells Inflammatory Inflammatory cytokines inflammatory protein inhalation Injury Intention interferon interleukin intravenous intravenous infusion Invasion IP10 lung Lungs Macrophage majority MCP1 Mesenchymal stem cells MIP1A mitigate monocyte monocyte chemotactic protein-1 MSC MSCs multitude myriad Necrosis organ PDGFB persistence Platelet platelet-derived growth factor positioned positive Protein receptor reduce respiratory Respiratory droplets RNA SARS-CoV-2 SARS-COV-2 infection secretion Secretome Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 sore throat STEM stem cell stem cells subunit supportive therapy symptomatic therapeutic therapy tissue TNF-α translational transmitted Treatment Tumor tumor necrosis tumor necrosis factor tumor necrosis factor alpha undergo Vascular virus widespread
[DOI] 10.3390/cells11142175 PMC 바로가기 [Article Type] Review

Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis

Article

Published on 2022-07-092022-10-06
Journal: EClinicalMedicine [Category] 진단,

[키워드] 95% CI adverse event AEs applied benefit cellular therapy China Chinese CNKI Cochrane Library control group Coronavirus disease-19 (COVID-19) COVID-19 Critical database Descriptive analysis development disease category dose doses Efficacy Efficacy and safety Egger Free heterogeneity in-hospital mortality in-hospital mortality rate Innovation less Mesenchymal stem cells Meta-analysis mortality rate MSC MSCs optics original Patient patients with COVID-19 Placebo plan Primary outcome Program reduce mortality Safe Safety Science searched Secondary outcomes significant difference small sample size standard care standard treatment stem cell stromal cell subgroup analysis Support systematic review technology the disease Tianjin Trade Treatment Trial two groups Valley was performed were used Wuhan
[DOI] 10.1016/j.eclinm.2022.101545 PMC 바로가기 [Article Type] Article

Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?

Reviews

Published on 2022-07-042022-10-05
Journal: Cell Death & Disease [Category] 바이오마커,

Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial

Clinical Trial

Published on 2022-07-042022-10-04
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상,

[키워드] acute respiratory distress acute respiratory distress syndrome adverse effect ARDS bone Bone marrow cells cellular cellular therapy clinical Cohort control patient control patients COVID-19 COVID-19 disease Critical D-dimer value Dexamethasone Efficacy Endocarditis evaluate extracorporeal membrane oxygenation group high mortality High-flow nasal oxygen Immune cell Immune-mediated induce Inflammation Inflammatory response intensive care intensive care unit (ICU) interval intravenous infusion invasive Invasive mechanical ventilation limit mechanical ventilation median Mesenchymal stromal cells MSC MSC-treated MSCs nasal no significant difference observation outcome oxygen Patient patients phase phenotype Randomized controlled trial Regulatory reported required requiring supplemental oxygen Result Safe SARS-CoV-2 severe COVID-19 significantly higher significantly lower Statistical tests stimulate stroke stromal cell survival syndrome therapy tissue repair treated Trial
[DOI] 10.3389/fimmu.2022.932360 PMC 바로가기 [Article Type] Clinical Trial

Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

Clinical Trial

Published on 2022-06-282022-10-05
Journal: Stem Cell Research & Therapy [Category] 임상,

[키워드] acute respiratory distress syndrome addition adverse effect approach ARDS ARDS patient ARDS patients Cell change clinical clinical trial control group correlated COVID-19 pandemic COVID-19 patient CRP level CT scan Cytokine storm demonstrated disease distress Features follow-up period functions IFN-g IL-10 IL-17 IL-1B IL-6 Inflammatory cytokines injection Intervention intervention group intravenous intravenous infusion Mesenchymal stromal cells Mild-to-moderate MSC MSCs Open-label Patient Registered registry required respiratory Safe Safety Sample size serum CRP serum cytokine serum cytokine level significant decrease significant increase single-center SPO standard care stromal cell study period syndrome therapy TNF-α UC-MSC UC-MSCs umbilical were assessed
[DOI] 10.1186/s13287-022-02920-1 PMC 바로가기 [Article Type] Clinical Trial

Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19

COVID-19에 대한 중간엽 줄기/기질 세포 기반 치료법: 살아있는 체계적인 검토 및 메타 분석의 첫 번째 반복: MSC 및 COVID-19

Meta-Analysis

Published on 2022-06-012022-09-11
Journal: Cytotherapy [Category] COVID19(2023년), SARS, 치료기술,

[키워드] 95% CI 95% confidence interval acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adherence adverse effects Analysis appear case sery Cell Cell-based therapy Clinical outcome Control coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria Critical determine Efficacy Endpoint estimate Exosomes Extracellular Extracellular vesicles Follow-up Future heterogeneity immunomodulatory interleukin-6 ISCT iteration Mesenchymal stem cells Mesenchymal stromal cells Meta-analysis Microvesicles moderate Mortality MSC MSCs nine not performed Other outcome Other outcomes pandemic patients patients with COVID-19 performed Pneumonia potential risk primary analysis random-effect random-effects repeated reported respiratory distress Respiratory distress syndrome risk risk of bia risk of death risk ratio RoB SARS-CoV-2 Secondary outcomes secreted Sepsis severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 standardized mean difference Statistical power stromal cells Study design systematic review therapy for COVID-19 tissue repair treat
[DOI] 10.1016/j.jcyt.2021.12.001 PMC 바로가기 [Article Type] Meta-Analysis